FIV gp120 Antibody (CE4-13B1): sc-65665

FIV gp120 Antibody (CE4-13B1) is a mouse monoclonal IgG2a antibody that detects FIV gp120 protein by western blotting (WB), immunofluorescence (IF), and flow cytometry (FCM). Anti-FIV gp120 antibody (CE4-13B1) is available as a non-conjugated format, specifically targeting FIV gp120 protein, which plays a crucial role in the viral life cycle of feline immunodeficiency virus (FIV). FIV gp120 protein is essential for viral attachment and entry into host cells through interactions with CD4 receptors and chemokine co-receptors on immune cell surfaces. Successful binding of FIV gp120 to these receptors enables viral envelope fusion with host cell membranes, facilitating delivery of viral genetic material into host cells. This process drives infection establishment and viral replication, leading to host immune system depletion. Understanding FIV gp120 function remains crucial for developing diagnostic tools and therapeutic strategies for managing FIV infections in domestic cats, while providing valuable insights for human immunodeficiency virus (HIV) research.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FIV gp120 Antibody (CE4-13B1) References:

1. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.  |  Giannecchini, S., et al. 2003. J Virol. 77: 3724-33. PMID: 12610147
2. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.  |  Lin, YC., et al. 2003. J Virol. 77: 6589-600. PMID: 12767979
3. T cell subpopulations mediating inhibition of feline immunodeficiency virus replication in mucosally infected cats.  |  Shimojima, M., et al. 2004. Microbes Infect. 6: 265-71. PMID: 15026013
4. Feline immunodeficiency virus subtypes A, B and C and intersubtype recombinants in Ontario, Canada.  |  Reggeti, F. and Bienzle, D. 2004. J Gen Virol. 85: 1843-1852. PMID: 15218168
5. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer.  |  Sinn, PL., et al. 2005. J Virol. 79: 12818-27. PMID: 16188984
6. Limited efficacy of an inactivated feline immunodeficiency virus vaccine.  |  Dunham, SP., et al. 2006. Vet Rec. 158: 561-2. PMID: 16632531
7. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats.  |  Dean, GA., et al. 2006. J Infect Dis. 193: 1520-7. PMID: 16652280
8. RNA in situ hybridization for the detection of Feline Immunodeficiency Virus in infected cells.  |  Ryan, G., et al. 2006. Southeast Asian J Trop Med Public Health. 37: 106-12. PMID: 16771221
9. Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties.  |  Pancino, G., et al. 1995. Virology. 206: 796-806. PMID: 7856093